KR20180023949A - 인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제 - Google Patents

인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제 Download PDF

Info

Publication number
KR20180023949A
KR20180023949A KR1020187000659A KR20187000659A KR20180023949A KR 20180023949 A KR20180023949 A KR 20180023949A KR 1020187000659 A KR1020187000659 A KR 1020187000659A KR 20187000659 A KR20187000659 A KR 20187000659A KR 20180023949 A KR20180023949 A KR 20180023949A
Authority
KR
South Korea
Prior art keywords
seq
hla
peptide
antibody
ebv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187000659A
Other languages
English (en)
Korean (ko)
Inventor
나이-콩 브이. 체웅
마히우딘 아메드
안드레스 로페즈-알바이테로
청 리우
홍 리우
징이 시앙
수 얀
Original Assignee
메모리얼 슬로안-케터링 캔서 센터
유레카 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안-케터링 캔서 센터, 유레카 쎄라퓨틱스, 인코포레이티드 filed Critical 메모리얼 슬로안-케터링 캔서 센터
Publication of KR20180023949A publication Critical patent/KR20180023949A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187000659A 2015-06-09 2016-06-09 인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제 Ceased KR20180023949A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562173330P 2015-06-09 2015-06-09
US62/173,330 2015-06-09
PCT/US2016/036735 WO2016201124A2 (en) 2015-06-09 2016-06-09 T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla

Publications (1)

Publication Number Publication Date
KR20180023949A true KR20180023949A (ko) 2018-03-07

Family

ID=57504187

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187000659A Ceased KR20180023949A (ko) 2015-06-09 2016-06-09 인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제

Country Status (12)

Country Link
US (2) US10501559B2 (cg-RX-API-DMAC10.html)
EP (1) EP3307319A4 (cg-RX-API-DMAC10.html)
JP (2) JP7000162B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180023949A (cg-RX-API-DMAC10.html)
CN (1) CN108289950B (cg-RX-API-DMAC10.html)
AU (1) AU2016274767B2 (cg-RX-API-DMAC10.html)
CA (1) CA2988768A1 (cg-RX-API-DMAC10.html)
HK (1) HK1252653A1 (cg-RX-API-DMAC10.html)
IL (2) IL281396B (cg-RX-API-DMAC10.html)
MX (1) MX2017015666A (cg-RX-API-DMAC10.html)
SG (1) SG10202110887PA (cg-RX-API-DMAC10.html)
WO (1) WO2016201124A2 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
IL281396B (en) 2015-06-09 2022-07-01 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
CN112041432A (zh) 2018-02-15 2020-12-04 纪念斯隆-凯特林癌症中心 Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
CN112189018A (zh) 2018-04-20 2021-01-05 汉诺威医学院 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
WO2020133050A1 (zh) * 2018-12-27 2020-07-02 深圳华大生命科学研究院 Ebv表位高亲和力t细胞受体
CA3127103A1 (en) * 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
CA3126707A1 (en) * 2019-01-29 2020-08-06 Gritstone Bio, Inc. Multispecific binding proteins
GB201901306D0 (en) * 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
WO2020191365A1 (en) 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
JP7674278B2 (ja) 2019-07-03 2025-05-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法
EP3786178A1 (en) * 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
CN114929743B (zh) * 2019-09-05 2026-01-02 纪念斯隆凯特琳癌症中心 抗steap1抗体及其用途
WO2021127184A1 (en) 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
WO2021211455A1 (en) * 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
CN111690617B (zh) * 2020-05-18 2023-05-02 李欣 抗eb病毒lmp2a的单克隆抗体及其细胞株和应用
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
CN114457165A (zh) * 2022-04-13 2022-05-10 深圳荻硕贝肯精准医学有限公司 一种用于检测hla-a02基因的引物探针组、试剂盒及检测方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68928427T2 (de) 1988-09-15 1998-06-04 Univ Columbia Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US6090381A (en) 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2392456A1 (en) 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
EP1294748B1 (en) 2000-03-27 2010-06-30 Technion Research and Development of Foundation, Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2004041849A1 (en) * 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
GB0917090D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
CN102812043A (zh) * 2009-11-19 2012-12-05 新加坡国立大学 用于制备t细胞受体样单克隆抗体的方法及其用途
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EA201401134A1 (ru) 2011-02-11 2015-05-29 Мемориал Слоан-Кеттеринг Кэнсер Сентер Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
ES2785081T3 (es) * 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN105555804B (zh) * 2013-08-07 2020-12-25 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
WO2015080981A1 (en) 2013-11-27 2015-06-04 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
WO2015199618A1 (en) 2014-06-24 2015-12-30 National University Of Singapore Epstein-barr virus lmp2 specific antibody and uses thereof
IL281396B (en) 2015-06-09 2022-07-01 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla

Also Published As

Publication number Publication date
EP3307319A4 (en) 2019-05-22
WO2016201124A3 (en) 2017-03-30
IL281396A (en) 2021-04-29
US20200115470A1 (en) 2020-04-16
US11168150B2 (en) 2021-11-09
SG10202110887PA (en) 2021-11-29
CN108289950B (zh) 2022-10-21
CA2988768A1 (en) 2016-12-15
HK1252653A1 (zh) 2019-05-31
JP7000162B2 (ja) 2022-02-10
JP2021106623A (ja) 2021-07-29
US20180258187A1 (en) 2018-09-13
AU2016274767A1 (en) 2018-01-04
MX2017015666A (es) 2018-07-06
CN108289950A (zh) 2018-07-17
US10501559B2 (en) 2019-12-10
JP2018520667A (ja) 2018-08-02
WO2016201124A2 (en) 2016-12-15
AU2016274767B2 (en) 2022-05-19
EP3307319A2 (en) 2018-04-18
IL281396B (en) 2022-07-01
IL256035A (en) 2018-01-31

Similar Documents

Publication Publication Date Title
US11168150B2 (en) T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
JP7153626B2 (ja) 抗ヒト４－１ｂｂ抗体およびその使用
US11384144B2 (en) T cell receptor-like antibodies specific for a PRAME peptide
KR102060389B1 (ko) 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
JP7022067B2 (ja) Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
AU2018360800A1 (en) Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
KR20180083859A (ko) 인간 cd19에 특이적인 항체 작용제 및 그의 용도
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
KR20170132793A (ko) Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
KR20200106498A (ko) 항-mct1 항체 및 그의 용도
CN105142668A (zh) 治疗性肽
CN111253486B (zh) 抗pd-1抗体及其用途
EP3998081A1 (en) Treatment of hematologic cancer with pd-1/cd3 dual specificity protein
HK1241907A1 (en) Antibody agents specific for human cd19 and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180109

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210604

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230329

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230609

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230329

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I